STOCK TITAN

Relmada Therapeutics Inc - RLMD STOCK NEWS

Welcome to our dedicated news page for Relmada Therapeutics (Ticker: RLMD), a resource for investors and traders seeking the latest updates and insights on Relmada Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Relmada Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Relmada Therapeutics's position in the market.

Rhea-AI Summary
Relmada Therapeutics, Inc. provided a corporate update and preliminary financial results for Q4 and full-year 2023. The company is advancing its Phase 3 program for REL-1017 for major depressive disorder. They also plan to initiate a Phase 1 trial for REL-P11 in obese patients. Financially, there was a decrease in R&D and an increase in G&A expenses for Q4 2023 compared to Q4 2022. The net loss for Q4 2023 was $25.2 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-17.41%
Tags
-
Rhea-AI Summary
Relmada Therapeutics (RLMD) to report Q4 and full-year 2023 financial results on March 19, 2024. The company will host a corporate update conference call and live webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.16%
Tags
conferences earnings
-
Rhea-AI Summary
Relmada Therapeutics, Inc. (RLMD) executives to participate in Leerink Partners Global Biopharma Conference for investor meetings in March 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
conferences
Rhea-AI Summary
Relmada Therapeutics, Inc. (RLMD) is well-positioned for a pivotal 2024 with multiple key clinical development milestones anticipated. The company's strong balance sheet will support it through all of 2024's expected critical catalysts in addressing diseases of the central nervous system (CNS). The ongoing Phase 3 program for REL-1017 as an adjunctive treatment for major depressive disorder (MDD) has made significant operational progress, completing a thorough analysis of study results and making important revisions to the clinical development plan. Additionally, advancements have been made in the non-psychedelic/low dose metabolic psilocybin program, with multiple clinical development milestones expected in 2024. Upcoming anticipated milestones include completing enrollment in REL-1017 study 302 and study 304, as well as commencing a Phase 1 trial in obese patients with steatotic liver disease to define the pharmacokinetic, safety, and tolerability profile of the company's modified-release psilocybin formulation (REL-P11).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.68%
Tags
none
-
Rhea-AI Summary
Relmada Therapeutics, Inc. (Nasdaq: RLMD) provided a corporate update and preliminary financial results for Q3 2023. The company is advancing its Phase 3 clinical development plan for REL-1017 as an adjunctive treatment for major depressive disorder. Recent preclinical data showed promising results for a modified-release psilocybin program. The company also announced upcoming milestones and financial results for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.33%
Tags
-
Rhea-AI Summary
Relmada Therapeutics, Inc. (Nasdaq: RLMD) will report its financial results for Q3 2023 on November 8, 2023. The company will host a corporate update conference call and live webcast at 4:30 p.m. ET. Webcast replay will be available on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.61%
Tags
conferences earnings
Rhea-AI Summary
Relmada Therapeutics announces new preclinical data on low-dose psilocybin for metabolic dysfunction-associated steatotic liver disease (MASLD)
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.13%
Tags
conferences clinical trial
-
Rhea-AI Summary
Relmada Therapeutics to participate in Jefferies Biotech CNS/Neuro Summit
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.63%
Tags
conferences
-
Rhea-AI Summary
Relmada Therapeutics to present three posters at 36th European College of Neuropsychopharmacology Congress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
conferences
Rhea-AI Summary
Relmada Therapeutics announces positive efficacy and safety results for REL-1017 in patients with Major Depressive Disorder (MDD).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.09%
Tags
Relmada Therapeutics Inc

Nasdaq:RLMD

RLMD Rankings

RLMD Stock Data

140.31M
25.61M
8.24%
46.28%
5.62%
Sporting and Athletic Goods Manufacturing
Manufacturing
Link
US
New York

About RLMD

relmada therapeutics (otcqb: rlmd) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. relmada has a diversified portfolio of four lead products at various stages of development including d-methadone (rel-1017) its n-methyl-d-aspartate (nmda) receptor antagonist for neuropathic pain; topical mepivacaine (rel-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (rel-1028) its oral dosage form of the opioid analgesic buprenorphine; and levocap er (rel-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. relmada’s product development efforts are guided by the internationally recognized scientific expertise of our research team. relmada’s approach is expected to reduce clinical development risks and